Infinium Pharmachem Limited IPO

Apply 0
Avoid 0

i. Infinium Pharmachem was incorporated with the objective of manufacturing and supplying of various pharma related chemicals, bulk drugs, pharma intermediates etc. Accordingly, the Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs).

ii. The Company penetrated the Pharmaceutical market with the CRAMS Model i.e. Contract Research & Manufacturing Services in which the Company emphasizes on:

– Process Optimization;
– Developing / Manufacturing the products specifically as per customer’s requirement and final application;
– Customized Packing / Labelling;
– Reliable Supply of final product;
– Highly focused to Iodine Chemistry.

iii. Today, the Company’s manufacturing capabilities and technical expertise have efficiently catered numerous industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics and much more.

iv. The Company currently provides the widest range of Iodine derivatives in the market, with more than 250+ intermediates and 15+ APIs.

v. The Company has developed and maintained long – term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies and its products reach out to over 250+ clients globally. The Company also formed a foreign Subsidiary as a Joint Venture (JV) with Shanghai Witofly Chemical Co. Ltd., in the name of Shanghai Tajilin Industrial Co. Ltd., in the People’s Republic of China in the year 2019.

 

Objects of the Infinium Pharmachem Limited IPO:

The proceeds from the fresh issue will be utilized for the following objects: 1. Marketing and branding expenses (including registration in reach - Europe, and other marketing expenses). 2. Repayment of some of the existing loans and expansion of units. 3. To meet incremental working capital requirements. 4. To meet public issue expenses.
DRHP of Infinium Pharmachem Limited IPO
RHP of Infinium Pharmachem Limited IPO

Infinium Pharmachem Limited IPO Details:

Open Date: Mar 31 2023
Close Date: Apr 05 2023
Total Shares: 1,875,000
Face Value: ₹ 10 Per Equity Share
Issue Type: Fixed Price Issue IPO
Issue Size: 25.31 Cr.
Lot Size: 1000 Shares
Issue Price: ₹ 135 Per Equity Share
Listing At: NSE Emerge
Listing Date: Apr 17 2023

Promoters And Management:

i. Mr. Sanjaykumar Viththalbhai Patel holds a Masters Degree from Gujarat University, Ahmedabad, Gujarat, with thorough understanding of Pharmaceutical Industry. He has been on the Board of Directors of the Company since its incorporation and was appointed as Director and currently he holds position of Chairman and Managing Director with effect from October 14th, 2022. He is primarily involved in the sales & marketing activities of the Company in global and domestic markets with sound business sense during last almost 20 years. ii. Mr. Pravin Bhadabhai Madhani is a gratuate from Surashtra University, Rajkot, Post graduate from M. S. University, Vadodara and L.L.B from Gujarat University, Ahmedabad. He has been on the Board of Directors of the Company since its incorporation. He looks after all the production related activities & regulatory matters of the Company. He has total experience of 20 years. He has earned credit of star performer during his three & a half year tenure with Government of Gujarat as a Mamlatdar. iii. Mr. Mitesh Lavjibhai Chikhaliya holds a master degree in International Business from Savitribai Phule, Pune University, Maharashtra. He is involved in the international business of the Company as well as Finance & Accounting affairs of the Company. He is having rich experience in global pharmaceutical industry. Mr. Chikhaliya joined the Board of Directors of the Company with effect from November 27th, 2010. Collectively, he has 14 years of rich experience.

Financials of Infinium Pharmachem Limited IPO:

P&L Statement
Particulars (in Lakhs) 2022 2021 2020
Revenue From Operations 9,912 7,053 3,884
COGS 5,422 4,198 2,830
Purchase of Stock-In-Trade 2,414 1,593 287
Change in Inventories -162 -306 -104
Employees Benefit Expenses 354 275 209
Other Expenses 881 797 413
EBITDA 1,003 496 249
OPM 10.12% 7.03% 6.41%
Other Income 93 62 57
Depreciation 63 65 58
Finance Cost 170 116 124
PBT 863 377 124
Tax 194 105 37
PAT 669 272 87
NPM 6.69% 3.82% 2.21%
Shares 69.58 69.58 69.58
EPS 9.6 3.90 1.20

Comparison With Peers:

Name of the Companies Revenue (Cr) Profit (Cr) EPS P/E CMP MCap
Infinium Pharmachem Limited 159 11 14 9.64 135 91
Samrat Pharmachem Limited 302 24 78.9 5.23 411 127

Recommendation on Infinium Pharmachem Limited IPO:

Review and Recommendation of Infinium Pharmachem IPO by IZ team is 6/10 1. The Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The Company currently provides the widest range of Iodine derivatives in the market, with more than 250+ intermediates and 15+ APIs 2. They have a manufacturing plant in Gujarat. 3. The Company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confidential solutions to its clients. 4. The Company has developed and maintained long - term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies and its products reach out to over 250+ clients globally. 5. Revenue of the company has increased from 38 Crores in FY20 to ~100 Crores in Fy22. 6. The EBITDA Margins have grown from 7.87% to 11% in the last 3 years. 7. PAT has increased from 93 lac in FY20 to 6 Crores in Fy22. 8. Company is raising 25 Cr funds to meet marketing expenses, payment of debt, expansion of existing unit, and working capital requirement. 9. Company has healthy ROCE of 25% and ROE of 24%. 10. Asking P/E based on FY23 annualised earnings is 9.63x.

Lead Manager of Infinium Pharmachem Limited IPO:

  1. Swastika Investmart Limited

Registrar of Infinium Pharmachem Limited IPO:

  1. Bigshare Services Private Limited

Company Address:

Infinium Pharmachem Limited 38 G.I.D.C Sojitra, Taluka - Sojitra, Dist. - Anand - 387240 Phone: +91-2692-238849 Email: info@infiniumpharmachem.com Website: https://infiniumpharmachem.com/

Discussion on Infinium Pharmachem Limited IPO:

Leave a Reply